In vivo expression of survivin and its splice variant survivin-2B: impact on clinical outcome in acute myeloid leukemia

International Journal of Cancer. Journal International Du Cancer
Mandy WagnerIngo Tamm

Abstract

Survivin, a member of the inhibitor of apoptosis protein family, is expressed in most human cancers, but undetectable in normal differentiated adult tissue in vivo. Because of this cancer-related expression, survivin is a promising target for cancer therapy. To determine the expression and prognostic role of survivin in acute myeloid leukemia (AML), we investigated the mRNA expression pattern of survivin and of the splice variants survivin-2B and survivin-DeltaEx3 in adult (n = 74) and children (n = 31) with de novo AML using RT-PCR. Survivin was the predominant transcript variant in AML cells, whereas significantly lower levels of survivin-2B and survivin-DeltaEx3 were observed (p < or = 0.0001). Neither expression of survivin nor of any splice variant correlated with maturation stage (FAB subtypes, immunophenotype) or cytogenetic risk groups. For AML cases treated according to AMLCG92 (adult) and AML-BFM93 (children) protocols, respectively, expression patterns were correlated with clinical data: in adult AML (n = 51), low expression of survivin-2B correlated with a better overall survival (p = 0.05; mean survival time 19 months vs. 9 months) and a better eventfree survival (p < or = 0.01; 27 months vs. 10 months). In childho...Continue Reading

References

Aug 7, 1999·The New England Journal of Medicine·H S SwanaD C Altieri
Nov 9, 2000·Proceedings of the National Academy of Sciences of the United States of America·D S O'ConnorD C Altieri
Nov 25, 2000·British Journal of Haematology·C AdidaH Dombret
Oct 6, 2001·Cancer Chemotherapy and Pharmacology·T BüchnerA Heinecke
Mar 22, 2002·The Lancet Oncology·I TammB Dörken
Jan 2, 2003·Nature Reviews. Cancer·Dario C Altieri
May 30, 2003·The EMBO Journal·Hiroyuki MarusawaJohn C Reed
Aug 28, 2003·Journal of Cellular Physiology·Fengzhi Li
Jan 27, 2004·Biochemical and Biophysical Research Communications·Adel BadranManabu Inuzuka
Jan 27, 2004·The American Journal of Pathology·Antonio MartinezDolors Colomer
May 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ellen J SchletteGeorge Z Rassidakis
Jun 3, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ingo TammChristian Wuchter
Dec 1, 2004·The Hematology Journal : the Official Journal of the European Haematology Association·Ingo TammChristian Wuchter

❮ Previous
Next ❯

Citations

Oct 22, 2011·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Keita TokuishiKatsunobu Kawahara
Jun 25, 2013·Cancer Letters·Rosalia de Necochea-CampionNathan R Wall
Feb 2, 2013·Genetic Testing and Molecular Biomarkers·Solmaz Moniri JavadhesariMonireh Halimi
Sep 5, 2006·Journal of Translational Medicine·Mads Hald AndersenPer thor Straten
Mar 31, 2012·Laboratory Hematology : Official Publication of the International Society for Laboratory Hematology·Azza Mostafa IbrahimHanan Mohamed Al Wakeel
Aug 21, 2007·Leukemia Research·Semra PaydasUmut Disel
May 16, 2009·Cancer Science·Yoshihiko HirohashiNoriyuki Sato
Dec 11, 2008·European Journal of Haematology·Katharina Salome MinkeKarl-Anton Kreuzer
Mar 21, 2009·British Journal of Haematology·Simone Fulda
Nov 22, 2007·International Journal of Cancer. Journal International Du Cancer·Mandy WagnerIngo Tamm
Dec 17, 2014·Immunological Reviews·Christopher N HahnDevendra K Hiwase
Jul 16, 2008·Expert Opinion on Therapeutic Targets·S M C LangemeijerJ H Jansen
Mar 20, 2008·Expert Opinion on Therapeutic Targets·Marzia PennatiNadia Zaffaroni
Feb 23, 2018·Leukemia·Alex C H WongJustin J-L Wong
Jun 7, 2008·Acta Biochimica Et Biophysica Sinica·Qi FeiJingde Zhu
Nov 18, 2018·British Journal of Haematology·Danielle M BranderJ Brice Weinberg
Sep 11, 2016·Journal of Hematology & Oncology·Rosalia de Necochea-CampionChien-Shing Chen
Nov 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jochen GreinerMichael Schmitt
Nov 29, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sophia AdamiaJames D Griffin

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.